BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19494241)

  • 1. Vascular regression and survival are differentially regulated by MT1-MMP and TIMPs in the aortic ring model of angiogenesis.
    Aplin AC; Zhu WH; Fogel E; Nicosia RF
    Am J Physiol Cell Physiol; 2009 Aug; 297(2):C471-80. PubMed ID: 19494241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase.
    Bigg HF; Morrison CJ; Butler GS; Bogoyevitch MA; Wang Z; Soloway PD; Overall CM
    Cancer Res; 2001 May; 61(9):3610-8. PubMed ID: 11325829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen improves TIMP-MMP balance and collagen distribution in volume-overloaded hearts of ovariectomized females.
    Voloshenyuk TG; Gardner JD
    Am J Physiol Regul Integr Comp Physiol; 2010 Aug; 299(2):R683-93. PubMed ID: 20504902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
    Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
    J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic interdomain interactions contribute to the inhibition of matrix metalloproteinases by tissue inhibitors of metalloproteinases.
    Remacle AG; Shiryaev SA; Radichev IA; Rozanov DV; Stec B; Strongin AY
    J Biol Chem; 2011 Jun; 286(23):21002-12. PubMed ID: 21518756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activity of a designer tissue inhibitor of metalloproteinases (TIMP)-1 against native membrane type 1 matrix metalloproteinase (MT1-MMP) in a cell-based environment.
    Lee MH; Atkinson S; Rapti M; Handsley M; Curry V; Edwards D; Murphy G
    Cancer Lett; 2010 Apr; 290(1):114-22. PubMed ID: 19815335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices.
    Davis GE; Pintar Allen KA; Salazar R; Maxwell SA
    J Cell Sci; 2001 Mar; 114(Pt 5):917-30. PubMed ID: 11181175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of matrix metalloproteinases and tissue inhibitors and extracellular matrix remodeling in aortic regurgitant hearts.
    Truter SL; Catanzaro DF; Supino PG; Gupta A; Carter J; Herrold EM; Dumlao TF; Borer JS
    Cardiology; 2009; 113(3):161-8. PubMed ID: 19129699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationships between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms.
    Nishimura K; Ikebuchi M; Kanaoka Y; Ohgi S; Ueta E; Nanba E; Ito H
    Int Angiol; 2003 Sep; 22(3):229-38. PubMed ID: 14612849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix.
    Collen A; Hanemaaijer R; Lupu F; Quax PH; van Lent N; Grimbergen J; Peters E; Koolwijk P; van Hinsbergh VW
    Blood; 2003 Mar; 101(5):1810-7. PubMed ID: 12393408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of tissue inhibitor of metalloproteinases-2 effect on pro-matrix metalloproteinase-2 activation by membrane-type 1 matrix metalloproteinase using baculovirus/insect-cell expression system.
    Jo Y; Yeon J; Kim HJ; Lee ST
    Biochem J; 2000 Feb; 345 Pt 3(Pt 3):511-9. PubMed ID: 10642509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs).
    Lafleur MA; Handsley MM; Knäuper V; Murphy G; Edwards DR
    J Cell Sci; 2002 Sep; 115(Pt 17):3427-38. PubMed ID: 12154073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in inflammation-induced corneal neovascularization.
    Ma DH; Chen JK; Kim WS; Hao YX; Wu HC; Tsai RJ; Hwang DG; Zhang F
    Ophthalmic Res; 2001; 33(6):353-62. PubMed ID: 11721189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of hormone replacement therapy in matrix metalloproteinase expression and intimal hyperplasia development after vascular injury.
    Mountain DJ; Freeman MB; Kirkpatrick SS; Cook RB; Chalk JE; Stevens SL; Goldman MH; Grandas OH
    Ann Vasc Surg; 2013 Apr; 27(3):337-45. PubMed ID: 23088810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteases and their inhibitors are produced by overlapping populations of activated astrocytes.
    Muir EM; Adcock KH; Morgenstern DA; Clayton R; von Stillfried N; Rhodes K; Ellis C; Fawcett JW; Rogers JH
    Brain Res Mol Brain Res; 2002 Apr; 100(1-2):103-17. PubMed ID: 12008026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MT1-MMP, but not secreted MMPs, influences the migration of human microvascular endothelial cells in 3-dimensional collagen gels.
    Koike T; Vernon RB; Hamner MA; Sadoun E; Reed MJ
    J Cell Biochem; 2002; 86(4):748-58. PubMed ID: 12210741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of matrix metalloproteinase-2 (MMP-2) by membrane type 1 matrix metalloproteinase through an artificial receptor for proMMP-2 generates active MMP-2.
    Nishida Y; Miyamori H; Thompson EW; Takino T; Endo Y; Sato H
    Cancer Res; 2008 Nov; 68(21):9096-104. PubMed ID: 18974156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting a Designer TIMP-1 to the Cell Surface for Effective MT1-MMP Inhibition: A Potential Role for the Prion Protein in Renal Carcinoma Therapy.
    Jiang B; Liu J; Lee MH
    Molecules; 2019 Jan; 24(2):. PubMed ID: 30641935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells.
    Zhong J; Gencay MM; Bubendorf L; Burgess JK; Parson H; Robinson BW; Tamm M; Black JL; Roth M
    J Cell Physiol; 2006 May; 207(2):540-52. PubMed ID: 16447244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.